Portola Pharmaceuticals is focused on the development of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. Portola’s wholly-owned compound, betrixaban, is a novel, oral, once-daily Factor Xa inhibitor in Phase 3 development for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Currently, there is no anticoagulant approved for … Continue reading Portola Pharmaceuticals
Boehringer Ingelheim Fremont, Inc. has made a significant long term investment in building a local presence in the Bay Area, since being acquired in 2011, and becoming a part of Boehringer Ingelheim’s biopharmaceutical contract manufacturing business “Boehringer Ingelheim BioXcellence‚Ñ¢”. In conjunction with Boehringer Ingelheim BioXcellence‚Ñ¢ sites in Biberach, Vienna and Shanghai, our facility in Fremont … Continue reading Boehringer-Ingelheim
With limited treatments available to patients with the deadliest form of skin cancer, the FDA approved ZELBORAF‚Ñ¢ and the cobas¬Æ BRAF Test which could increase survival for 50 percent of patients with melanoma. A breakthrough accomplishment in personalized medicine, this approach made the drug available to patients in less than six years from the discovery … Continue reading Zelboraf‚Ñ¢ and cobas¬Æ BRAFV600E Test by Plexxikon Inc. Genentech/Roche Roche Molecular Diagnostics
A native of Montevideo, Uruguay, Dr. Zaffaroni received his B.Sc. from the University of Montevideo, and his PhD in biochemistry from the University of Rochester. In 1951 he joined Syntex Corporation in Mexico, where his pioneering work on the development of the birth control pill transformed Syntex into a major pharmaceutical company. Eventually Dr. Zaffaroni … Continue reading Alejandro Zaffaroni, Ph.D.
Versant Ventures is a leading healthcare-focused venture capital firm specializing in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services, and healthcare information technology. The firm, founded in 1999, consists of a seasoned team of twelve managing directors with more than 130 years of venture capital investing experience and more than 150 years of … Continue reading Versant Ventures
Veracyte, Inc., based in South San Francisco, Calif., is a pioneer in molecular cytology, focused on discovering, developing and commercializing pre-operative molecular diagnostic solutions in oncology and other major disease areas. The company aims to improve patient care by increasing the diagnostic accuracy of cytology samples. This will enable physicians to make more informed treatment … Continue reading Veracyte
Marty Van Duyn is the Assistant City Manager with the City of South San Francisco. He brings more than 40 years of experience as an urban planner and a leader in redevelopment, city management, and economic development for a variety of cities and states. Mr. Van Duyn joined the City of South San Francisco in … Continue reading Marty Van Duyn
Pablo D.T. Valenzuela is a Chilean biochemist dedicated to biotechnology development. He is one of the cofounders of Chiron Corporation (1981). Together with Ed Penhoet and Bill Rutter he built Chiron into one of the three emblematic biotechnology companies in the US and San Francisco Bay Area. Under the scientific direction of Dr. Valenzuela, Chiron … Continue reading Pablo D.T. Valenzuela, Ph.D.
Tethys Bioscience is a predictive personalized medicine company developing novel tests which address the growing global healthcare challenge of chronic diseases such as diabetes. Founded in 2005, the company integrates an experienced management team, innovative research based on sound science, a CLIA-licensed clinical laboratory, and a commercialization team with extensive experience in diagnostic innovation. Tethys … Continue reading Tethys Bioscience, Inc.
Chris Somerville is the Director of the Carnegie Institution for Science, Department of Plant Biology, a professor in the Department of Biological Sciences at Stanford University and a visiting scientist at Lawrence Berkeley National Laboratory. Somerville is an acting director of the Energy Biosciences Institute (EBI), a new research and development organization that will bring … Continue reading Chris Somerville, PhD